These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19414853)

  • 1. Rejuvenation in older adults receiving oral ghrelin.
    Webster J
    Ann Intern Med; 2009 May; 150(9):654-5; author reply 655. PubMed ID: 19414853
    [No Abstract]   [Full Text] [Related]  

  • 2. Rejuvenation in older adults receiving oral ghrelin.
    Gaugg M
    Ann Intern Med; 2009 May; 150(9):654; author reply 655. PubMed ID: 19414852
    [No Abstract]   [Full Text] [Related]  

  • 3. Rejuvenation in older adults receiving oral ghrelin.
    Rafael H
    Ann Intern Med; 2009 May; 150(9):653-4; author reply 655. PubMed ID: 19414850
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
    Nass R; Pezzoli SS; Oliveri MC; Patrie JT; Harrell FE; Clasey JL; Heymsfield SB; Bach MA; Vance ML; Thorner MO
    Ann Intern Med; 2008 Nov; 149(9):601-11. PubMed ID: 18981485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summaries for patients. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.
    Ann Intern Med; 2008 Nov; 149(9):I-36. PubMed ID: 18981483
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time.
    Blackman MR
    Ann Intern Med; 2008 Nov; 149(9):677-9. PubMed ID: 18981489
    [No Abstract]   [Full Text] [Related]  

  • 7. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia and the elusive fountain of youth.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2009 Jan; 6(1):1. PubMed ID: 19127276
    [No Abstract]   [Full Text] [Related]  

  • 9. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
    Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
    Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.
    Lee J; Kwon A; Chae HW; Lee WJ; Kim TH; Kim HS
    Yonsei Med J; 2018 Dec; 59(10):1174-1180. PubMed ID: 30450851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
    Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
    J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
    Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid hormone modulates food intake and glycemia via ghrelin secretion in Zucker fatty rats.
    Patel K; Joharapurkar A; Dhanesha N; Patel V; Kshirsagar S; Raval P; Raval S; Jain MR
    Drug Res (Stuttg); 2014 Oct; 64(10):523-9. PubMed ID: 24357139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.
    Gollner A; Rudolph D; Arnhof H; Bauer M; Blake SM; Boehmelt G; Cockroft XL; Dahmann G; Ettmayer P; Gerstberger T; Karolyi-Oezguer J; Kessler D; Kofink C; Ramharter J; Rinnenthal J; Savchenko A; Schnitzer R; Weinstabl H; Weyer-Czernilofsky U; Wunberg T; McConnell DB
    J Med Chem; 2016 Nov; 59(22):10147-10162. PubMed ID: 27775892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.
    Patchett AA; Nargund RP; Tata JR; Chen MH; Barakat KJ; Johnston DB; Cheng K; Chan WW; Butler B; Hickey G
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7001-5. PubMed ID: 7624358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
    J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
    Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.